These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36158143)

  • 41. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
    Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
    Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
    Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
    Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.
    Naaman SC; Bakris GL
    Diabetes Care; 2023 Sep; 46(9):1574-1586. PubMed ID: 37625003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GLP-1 Receptor Agonists and Kidney Protection.
    Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
    Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
    Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Am J Kidney Dis; 2014 Oct; 64(4):510-33. PubMed ID: 25257325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
    Sato A; Nishimoto M
    Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.
    Georgianos PI; Vaios V; Roumeliotis S; Leivaditis K; Eleftheriadis T; Liakopoulos V
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The residual cardiorenal risk in type 2 diabetes.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease.
    Wu X; Zhao L; Zhang Y; Li K; Yang J
    Front Physiol; 2023; 14():1166685. PubMed ID: 37153213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
    Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A;
    Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.
    Mallik R; Chowdhury TA
    Ther Adv Endocrinol Metab; 2022; 13():20420188221081601. PubMed ID: 35281302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
    Karalliedde J; Winocour P; Chowdhury TA; De P; Frankel AH; Montero RM; Pokrajac A; Banerjee D; Dasgupta I; Fogarty D; Sharif A; Wahba M; Mark PB; Zac-Varghese S; Patel DC; Bain SC
    Diabet Med; 2022 Apr; 39(4):e14769. PubMed ID: 35080257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.